Marker Therapeutics, Inc.

MARKER THERAPEUTICS

T-cell pharmaceutical products for the treatment of cancer;THERAPEUTICS;Biotechnology services, namely, the development of T-cell pharmaceutical products and technologies for use in the treatment of cancer;

POLYSTART

chimeric nucleic acid vector delivery systems administered in vivo or ex vivo to evaluate or elevate the expression of an encoded polypeptide or selected antigenic epitopes for medical purposes; chimeric nucleic acid administered in vivo or ex vivo to evaluate or elevate the expression of an encoded polypeptide or selected antigenic epitopes for medical purposes; chimeric nucleic acid-based immunotherapeutic and immunoprophylactic vaccines for the treatment of cancer and infectious disease; vaccine adjuvants;chimeric nucleic acid and nucleic acid molecules for scientific use, namely, research and development use and for use in the manufacture of pharmaceuticals; chimeric nucleic acid and nucleic acid molecules for use in the manufacture of recombinant nucleic acids and recombinant polypeptides/proteins/antigenic determinants encoded thereby;Medical and scientific research and development services in the field of vaccine technology specific to oncology or infectious diseases; Medical and scientific research and development services in the field of vaccine technology; Medical and scientific research and development services in the fields of nucleic acid expression technology, and evaluation of expressed protein, polypeptide, or antigenic epitopes; consulting services in the field of protein expression, vaccine technology, and the elevation of the expression of selected proteins, polypeptides and antigenic epitopes;